You are using an unsupported browser. Please upgrade your browser to a newer version to get the best experience on DrugBank.
Identification
NamePrednisolone
Accession NumberDB00860  (APRD00197)
TypeSmall Molecule
GroupsApproved, Vet Approved
DescriptionA glucocorticoid with the general properties of the corticosteroids. It is the drug of choice for all conditions in which routine systemic corticosteroid therapy is indicated, except adrenal deficiency states. [PubChem]
Structure
Thumb
Synonyms
(11beta)-11,17,21-Trihydroxypregna-1,4-diene-3,20-dione
1,4-Pregnadiene-11beta,17alpha,21-triol-3,20-dione
1,4-Pregnadiene-3,20-dione-11beta,17alpha,21-triol
3,20-dioxo-11beta,17alpha,21-Trihydroxy-1,4-pregnadiene
delta-dehydrocortisol
delta-dehydrohydrocortisone
delta-hydrocortisone
delta(1)-Dehydrocortisol
delta(1)-Dehydrohydrocortisone
delta(1)-Hydrocortisone
Hydroretrocortine
Metacortandralone
PRDL
Prednisolona
Prednisolonum
External Identifiers Not Available
Approved Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Ak Tate Oph Sus 1%suspension1 %ophthalmicSandoz Canada Incorporated1985-12-312008-08-07Canada
Diopred Suspension 1%suspension1 %ophthalmicSandoz Canada Incorporated1994-12-31Not applicableCanada
Flo-predsuspension15 mg/5mLoralTaro Pharmaceuticals U.S.A., Inc.2008-01-17Not applicableUs
Inflamase Forte Oph Soln 1%liquid10 mgophthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Inflamase Forte Ophthalmic Solution 1%solution1 %ophthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1996-08-202004-07-13Canada
Inflamase Mildliquid.125 %ophthalmicNovartis Ophthalmics Novartis Pharmaceuticals (Canada) Inc1995-12-312002-07-04Canada
Inflamase Oph Soln 0.125%liquid1.25 mgophthalmicIolab Pharmaceuticals1988-12-311996-09-09Canada
Minims Prednisolone Sodium Phosphate 0.5%drops0.5 %ophthalmic; topicalValeant Canada Lp/valeant Canada s.e.c.1995-12-31Not applicableCanada
Novo-prednisolone 5mgtablet5 mgoralNovopharm Limited1967-12-312005-08-10Canada
Omnipredsuspension10 mg/mLophthalmicAlcon Laboratories, Inc.2007-11-06Not applicableUs
Orapred ODTtablet, orally disintegrating10 mg/1oralShionogi Inc.2006-06-01Not applicableUs
Orapred ODTtablet, orally disintegrating15 mg/1oralShionogi Inc.2006-06-01Not applicableUs
Orapred ODTtablet, orally disintegrating10 mg/1oralConcordia Pharmaceuticals Inc.2006-06-01Not applicableUs
Orapred ODTtablet, orally disintegrating30 mg/1oralShionogi Inc.2006-06-01Not applicableUs
Orapred ODTtablet, orally disintegrating15 mg/1oralConcordia Pharmaceuticals Inc.2006-06-01Not applicableUs
Orapred ODTtablet, orally disintegrating30 mg/1oralConcordia Pharmaceuticals Inc.2006-06-01Not applicableUs
Pediapredliquid5 mgoralSanofi Aventis Canada Inc1998-09-23Not applicableCanada
Pediapred - Liq 6.7mg/5mlliquid5 mgoralFisons Corporation Ltd.1995-12-311998-08-12Canada
PMS-prednisolonesolution5 mgoralPharmascience Inc2002-03-19Not applicableCanada
PMS-prednisolone Sod Phos Oph Sol Forte 1%drops1 %ophthalmicPharmascience Inc1992-12-31Not applicableCanada
Pred Fortesuspension/ drops10 mg/mLophthalmicA S Medication Solutions Llc1973-06-01Not applicableUs
Pred Fortesuspension/ drops10 mg/mLophthalmicA S Medication Solutions Llc1973-06-01Not applicableUs
Pred Fortesuspension/ drops10 mg/mLophthalmicAllergan, Inc.1973-06-01Not applicableUs
Pred Forte 1%drops1 %ophthalmicAllergan Inc1974-12-31Not applicableCanada
Pred Mildsuspension/ drops1.2 mg/mLophthalmicPreferred Pharmaceuticals, Inc2012-03-05Not applicableUs
Pred Mildsuspension/ drops1.2 mg/mLophthalmicAllergan, Inc.1972-12-01Not applicableUs
Pred Mildsuspension/ drops1.2 mg/mLophthalmicPhysicians Total Care, Inc.2012-11-01Not applicableUs
Pred Mild 0.12%drops0.12 %ophthalmicAllergan Inc1974-12-31Not applicableCanada
Prednisolone Acetatesuspension/ drops10 mg/mLophthalmicPreferred Pharmaceuticals, Inc.2012-10-23Not applicableUs
Prednisolone Acetatesuspension10 mg/mLophthalmicClinical Solutions Wholesale1994-12-15Not applicableUs
Prednisolone Acetatesuspension/ drops10 mg/1ophthalmicREMEDYREPACK INC.2013-04-12Not applicableUs
Prednisolone Acetatesuspension10 mg/mLophthalmicPhysicians Total Care, Inc.2002-11-04Not applicableUs
Prednisolone Acetatesuspension/ drops10 mg/mLophthalmicH.J. Harkins Company, Inc.1997-08-19Not applicableUs
Prednisolone Acetatesuspension/ drops10 mg/mLophthalmicPacific Pharma, Inc.1997-08-19Not applicableUs
Prednisolone Acetatesuspension/ drops10 mg/mLophthalmicSandoz Inc.1994-12-15Not applicableUs
Prednisolone Acetate Ophthalmic Suspension USP 1%suspension1 %ophthalmicBausch & Lomb Pharmaceuticals Inc.Not applicableNot applicableCanada
Prednisolone Sodium Phosphatetablet, orally disintegrating30 mg/1oralPrasco Laboratories2015-10-21Not applicableUs
Prednisolone Sodium Phosphatesolution5 mg/5mLoralSeton Pharmaceuticals, Llc2013-10-18Not applicableUs
Prednisolone Sodium Phosphate 1% Fortedrops; liquid1 %ophthalmicRivex Ophthalmics Inc.1997-05-072003-07-28Canada
Prednisolone Sodium Phosphate ODTtablet, orally disintegrating10 mg/1oralPrasco Laboratories2015-10-21Not applicableUs
Prednisolone Sodium Phosphate ODTtablet, orally disintegrating15 mg/1oralPrasco Laboratories2015-10-21Not applicableUs
R.O.-predphate Tm Fortedrops; liquid1 %ophthalmicRichmond Pharmaceuticals Inc.1992-12-311997-08-11Canada
Ratio-prednisolonesuspension1 %ophthalmicTeva Canada Limited1986-12-31Not applicableCanada
Sab-prednasesolution1 %ophthalmicSabex IncNot applicableNot applicableCanada
Sandoz Prednisolonesuspension0.12 %ophthalmicSandoz Canada Incorporated1993-12-31Not applicableCanada
Sandoz Prednisolonesuspension1 %ophthalmicSandoz Canada Incorporated1993-12-31Not applicableCanada
Approved Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Millipredtablet5 mg/5mgoralLaser Pharmaceuticals, LLC2008-10-01Not applicableUs
Millipredtablet5 mg/1oralZylera Pharmaceuticals, LLC2014-03-01Not applicableUs
Millipredsolution10 mg/5mLoralZylera Pharmaceuticals, LLC2014-03-01Not applicableUs
Millipredsolution10 mg/5mLoralLaser Pharmaceuticals, LLC2009-07-01Not applicableUs
Orapredsolution15 mg/5mLoralShionogi Inc.2000-12-142016-02-22Us
Pediapredsolution5 mg/5mLoralRoyal Pharmaceuticals2003-03-26Not applicableUs
Prednisolonesolution15 mg/5mLoralMed Vantx, Inc.1998-12-11Not applicableUs
Prednisolonesolution15 mg/5mLoralTeva Pharmaceuticals USA Inc1998-12-11Not applicableUs
Prednisolonesyrup15 mg/5mLoralEthex Corporation2004-05-10Not applicableUs
Prednisolonesyrup15 mg/5mLoralPhysicians Total Care, Inc.2003-02-28Not applicableUs
Prednisolonesolution15 mg/5mLoralDispensing Solutions, Inc.2003-02-27Not applicableUs
Prednisolonesolution15 mg/5mLoralHi Tech Pharmacal Co., Inc.2003-02-27Not applicableUs
Prednisolonesolution15 mg/5mLoralRebel Distributors Corp2003-02-27Not applicableUs
Prednisolonesolution15 mg/5mLoralAidarex Pharmaceuticals LLC1998-12-11Not applicableUs
Prednisolonesolution15 mg/5mLoralProficient Rx LP2003-02-27Not applicableUs
Prednisolonesolution15 mg/5mLoralApotheca Inc.2003-02-27Not applicableUs
Prednisolonesolution15 mg/5mLoralPreferred Pharmaceuticals, Inc2003-02-27Not applicableUs
Prednisolonesyrup15 mg/5mLoralQualitest Pharmaceuticals2007-09-21Not applicableUs
Prednisolonesyrup5 mg/5mLoralPhysicians Total Care, Inc.2003-02-28Not applicableUs
Prednisolonesyrup15 mg/5mLoralPreferred Pharmaceuticals, Inc.2013-10-25Not applicableUs
Prednisolonesolution15 mg/5mLoralDIRECT RX2014-01-01Not applicableUs
Prednisolonesyrup15 mg/5mLoralClinical Solutions Wholesale2007-09-21Not applicableUs
Prednisolonesolution15 mg/5mLoralStat Rx USA2003-02-27Not applicableUs
Prednisolone Sodium Phosphatesolution5 mg/5mLoralHi Tech Pharmacal Co., Inc.2003-03-26Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralQualitest Pharmaceuticals2009-05-26Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralAtlantic Biologicals Corps2005-05-25Not applicableUs
Prednisolone Sodium Phosphatesolution/ drops10 mg/mLophthalmicMwi/Vet One1994-07-29Not applicableUs
Prednisolone Sodium Phosphatesolution/ drops10 mg/mLophthalmicBausch & Lomb Incorporated1994-07-29Not applicableUs
Prednisolone Sodium Phosphatetablet, orally disintegrating15 mg/1oralMylan Pharmaceuticals Inc.2014-12-08Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralProficient Rx LP2005-04-25Not applicableUs
Prednisolone Sodium Phosphatesolution/ drops10 mg/mLophthalmicButler Animal Health Supply1994-07-29Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralPharmaceutical Associates, Inc.2005-04-25Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralPhysicians Total Care, Inc.2005-03-03Not applicableUs
Prednisolone Sodium Phosphatetablet, orally disintegrating30 mg/1oralMylan Pharmaceuticals Inc.2014-12-08Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralUnit Dose Services2005-04-25Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralMorton Grove Pharmaceuticals, Inc.2004-10-04Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralCardinal Health2004-10-04Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralAmneal Pharmaceuticals of New York, LLC2009-12-01Not applicableUs
Prednisolone Sodium Phosphatesolution15 mg/5mLoralRebel Distributors Corp2009-12-01Not applicableUs
Prednisolone Sodium Phosphatesolution5 mg/5mLoralSeton Pharmaceuticals2003-03-26Not applicableUs
Prednisolone Sodium Phosphatetablet, orally disintegrating10 mg/1oralMylan Pharmaceuticals Inc.2014-12-08Not applicableUs
Prednisolone Sodium Phosphate Oral Solutionsolution25 mg/5mLoralMission Pharmacal Company2012-10-01Not applicableUs
Veripred 20solution20 mg/5mLoralZylera Pharmaceuticals, LLC2014-08-01Not applicableUs
Approved Over the Counter ProductsNot Available
Unapproved/Other Products Not Available
International Brands
NameCompany
Ak-PredNot Available
Decortin HNot Available
Delta-CortefNot Available
DeltacortrilNot Available
HydeltraNot Available
Hydeltra-TBANot Available
HydeltrasolNot Available
InflamaseNot Available
Key-PredNot Available
KlismacortNot Available
MeticorteloneNot Available
PanafcorteloneNot Available
PrecortalonNot Available
PredonineNot Available
PreloneNot Available
SoloneNot Available
SteroloneNot Available
UltracortenolNot Available
Brand mixtures
NameLabellerIngredients
BlephamideAllergan, Inc.
Blephamide Oph OntAllergan Inc
Blephamide Opht SuspensionAllergan Inc
Dioptimyd OintmentDioptic Pharmaceuticals Inc
Dioptimyd SuspensionDioptic Pharmaceuticals Inc
Metimyd Oph SusSchering Plough Canada Inc
Odan-cideOdan Laboratories Ltd
Pred-GAllergan, Inc.
Sulfacetamide Sodium and Prednisolone Sodium PhosphateRebel Distributors Corp
Vasocidin Ophthalmic SolutionIolab Pharmaceuticals
Salts
Name/CASStructureProperties
Prednisolone acetate
Thumb
  • InChI Key: LRJOMUJRLNCICJ-JZYPGELDSA-N
  • Monoisotopic Mass: 402.204238692
  • Average Mass: 402.4807
DBSALT000254
Prednisolone sodium phosphate
125-02-0
Thumb
  • InChI Key: VJZLQIPZNBPASX-WFFZFITINA-L
  • Monoisotopic Mass: 484.123893702
  • Average Mass: 484.3876
DBSALT000785
prednisolone sodium succinate
ThumbNot applicableDBSALT001634
Prednisolone tebutate
7681-14-3
Thumb
  • InChI Key: HUMXXHTVHHLNRO-KAJVQRHHSA-N
  • Monoisotopic Mass: 458.266838948
  • Average Mass: 458.587
DBSALT000786
Prednisolone tertiary butylacetate
ThumbNot applicableDBSALT001635
Categories
UNII9PHQ9Y1OLM
CAS number50-24-8
WeightAverage: 360.444
Monoisotopic: 360.193674006
Chemical FormulaC21H28O5
InChI KeyInChIKey=OIGNJSKKLXVSLS-VWUMJDOOSA-N
InChI
InChI=1S/C21H28O5/c1-19-7-5-13(23)9-12(19)3-4-14-15-6-8-21(26,17(25)11-22)20(15,2)10-16(24)18(14)19/h5,7,9,14-16,18,22,24,26H,3-4,6,8,10-11H2,1-2H3/t14-,15-,16-,18+,19-,20-,21-/m0/s1
IUPAC Name
(1S,2R,10S,11S,14R,15S,17S)-14,17-dihydroxy-14-(2-hydroxyacetyl)-2,15-dimethyltetracyclo[8.7.0.0²,⁷.0¹¹,¹⁵]heptadeca-3,6-dien-5-one
SMILES
[H][C@@]12CC[C@](O)(C(=O)CO)[C@@]1(C)C[[email protected]](O)[C@@]1([H])[C@@]2([H])CCC2=CC(=O)C=C[C@]12C
Taxonomy
DescriptionThis compound belongs to the class of organic compounds known as 21-hydroxysteroids. These are steroids carrying a hydroxyl group at the 21-position of the steroid backbone.
KingdomOrganic compounds
Super ClassLipids and lipid-like molecules
ClassSteroids and steroid derivatives
Sub ClassHydroxysteroids
Direct Parent21-hydroxysteroids
Alternative Parents
Substituents
  • 21-hydroxysteroid
  • Progestogin-skeleton
  • Pregnane-skeleton
  • 20-oxosteroid
  • 17-hydroxysteroid
  • 11-hydroxysteroid
  • 11-beta-hydroxysteroid
  • Oxosteroid
  • 3-oxosteroid
  • 3-oxo-delta-1,4-steroid
  • Delta-1,4-steroid
  • Tertiary alcohol
  • Cyclic alcohol
  • Alpha-hydroxy ketone
  • Cyclic ketone
  • Secondary alcohol
  • Ketone
  • Hydrocarbon derivative
  • Primary alcohol
  • Organooxygen compound
  • Carbonyl group
  • Alcohol
  • Aliphatic homopolycyclic compound
Molecular FrameworkAliphatic homopolycyclic compounds
External Descriptors
Pharmacology
IndicationFor the treatment of primary or secondary adrenocortical insufficiency, such as congenital adrenal hyperplasia, thyroiditis. Also used to treat psoriatic arthritis, rheumatoid arthritis, ankylosing spondylitis, bursitis, acute gouty arthritis and epicondylitis. Also indicated for treatment of systemic lupus erythematosus, pemphigus and acute rhematic carditis. Can be used in the treatment of leukemias, lymphomas, thrombocytopenia purpura and autoimmune hemolytic anemia. Can be used to treat celiac disease, insulin resistance, ulcerative colitis and liver disorders.
PharmacodynamicsPrednisolone is a synthetic glucocorticoid used as antiinflammatory or immunosuppressive agent. Prednisolone is indicated in the treatment of various conditions, including congenital adrenal hyperplasia, psoriatic arthritis, systemic lupus erythematosus, bullous dermatitis herpetiformis, seasonal or perennial allergic rhinitis, allergic corneal marginal ulcers, symptomatic sarcoidosis, idiopathic thrombocytopenic purpura in adults, leukemias and lymphomas in adults, and ulcerative colitis. Glucocorticoids are adrenocortical steroids and cause profound and varied metabolic effects. In addition, they modify the body's immune responses to diverse stimuli.
Mechanism of actionGlucocorticoids such as Prednisolone can inhibit leukocyte infiltration at the site of inflammation, interfere with mediators of inflammatory response, and suppress humoral immune responses. The antiinflammatory actions of glucocorticoids are thought to involve phospholipase A2 inhibitory proteins, lipocortins, which control the biosynthesis of potent mediators of inflammation such as prostaglandins and leukotrienes. Prednisolone reduces inflammatory reaction by limiting the capillary dilatation and permeability of the vascular structures. These compounds restrict the accumulation of polymorphonuclear leukocytes and macrophages and reduce the release of vasoactive kinins. Recent research suggests that corticosteroids may inhibit the release of arachidonic acid from phospholipids, thereby reducing the formation of prostaglandins. Prednisolone is a glucocorticoid receptor agonist. On binding, the corticoreceptor-ligand complex translocates itself into the cell nucleus, where it binds to many glucocorticoid response elements (GRE) in the promoter region of the target genes. The DNA bound receptor then interacts with basic transcription factors, causing an increase or decrease in expression of specific target genes, including suppression of IL2 (interleukin 2) expression.
Related Articles
AbsorptionReadily absorbed by gastrointestinal tract, peak plasma concentration is reached 1-2 hours after administration.
Volume of distributionNot Available
Protein bindingVery high (>90%)
Metabolism

Excreted in the urine as either free or glucoconjugate.

Route of eliminationNot Available
Half life2-3 hours
ClearanceNot Available
ToxicityLD50=500 mg/kg (oral, rat), short-term side effects include high blood glucose levels and fluid retention. Long term side effects include Cushing's syndrome, weight gain, osteoporosis, glaucoma, type II diabetes and adrenal suppression.
Affected organisms
  • Humans and other mammals
Pathways
PathwayCategorySMPDB ID
Prednisone Action PathwayDrug actionSMP00440
Prednisolone Action PathwayDrug actionSMP00441
Prednisone Metabolism PathwayDrug metabolismSMP00631
Prednisolone Metabolism PathwayDrug metabolismSMP00632
SNP Mediated EffectsNot Available
SNP Mediated Adverse Drug ReactionsNot Available
ADMET
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.9918
Blood Brain Barrier+0.9383
Caco-2 permeable-0.5096
P-glycoprotein substrateSubstrate0.7861
P-glycoprotein inhibitor INon-inhibitor0.7847
P-glycoprotein inhibitor IINon-inhibitor0.8383
Renal organic cation transporterNon-inhibitor0.7463
CYP450 2C9 substrateNon-substrate0.8496
CYP450 2D6 substrateNon-substrate0.9138
CYP450 3A4 substrateSubstrate0.7407
CYP450 1A2 substrateNon-inhibitor0.9406
CYP450 2C9 inhibitorNon-inhibitor0.9072
CYP450 2D6 inhibitorNon-inhibitor0.9418
CYP450 2C19 inhibitorNon-inhibitor0.9253
CYP450 3A4 inhibitorNon-inhibitor0.8902
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9095
Ames testNon AMES toxic0.9132
CarcinogenicityNon-carcinogens0.9597
BiodegradationNot ready biodegradable0.925
Rat acute toxicity1.8914 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.95
hERG inhibition (predictor II)Non-inhibitor0.584
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397 )
Pharmacoeconomics
Manufacturers
  • Pharmacia and upjohn co
  • Akorn inc
  • Sandoz canada inc
  • Teva parenteral medicines inc
  • Watson laboratories inc
  • Bel mar laboratories inc
  • Schering corp sub schering plough corp
  • Alpharma uspd inc
  • Apotex inc richmond hill
  • Hi tech pharmacal co inc
  • Ivax pharmaceuticals inc sub teva pharmaceuticals usa
  • Kv pharmaceutical co
  • Pharmaceutical assoc inc div beach products
  • Teva pharmaceuticals usa
  • Vintage pharmaceuticals llc
  • We pharmaceuticals inc
  • Wockhardt eu operations (swiss) ag
  • Muro pharmaceutical inc
  • Teva pharmaceuticals usa inc
  • Halsey drug co inc
  • Ferndale laboratories inc
  • Barr laboratories inc
  • Cm bundy co
  • Elkins sinn div ah robins co inc
  • Everylife
  • John j ferrante
  • Heather drug co inc
  • Impax laboratories inc
  • Inwood laboratories inc sub forest laboratories inc
  • Lannett co inc
  • Marshall pharmacal corp
  • Panray corp sub ormont drug and chemical co inc
  • L perrigo co
  • Phoenix laboratories inc
  • Purepac pharmaceutical co
  • Private formulations inc
  • Roxane laboratories inc
  • Sandoz inc
  • Sperti drug products inc
  • Superpharm corp
  • Tablicaps inc
  • Udl laboratories inc
  • Valeant pharmaceuticals international
  • Vitarine pharmaceuticals inc
  • West ward pharmaceutical corp
  • Whiteworth towne paulsen inc
  • Pfizer laboratories div pfizer inc
  • Central pharmaceuticals inc
  • Alcon laboratories inc
  • Allergan pharmaceutical
  • Taro pharmaceuticals usa inc
  • Merck and co inc
  • Novartis pharmaceuticals corp
  • Pharmafair inc
  • Alcon universal ltd
  • Bausch and lomb pharmaceuticals inc
  • Sola barnes hind
  • Shionogi pharma inc
  • Ucb inc
  • Amneal pharmaceuticals
  • Paddock laboratories inc
  • Pharmaceutical assoc inc
Packagers
Dosage forms
FormRouteStrength
Dropsophthalmic
Ointmentophthalmic; topical
Suspensionophthalmic
Suspensionoral15 mg/5mL
Liquidophthalmic10 mg
Solutionophthalmic1 %
Liquidophthalmic.125 %
Liquidophthalmic1.25 mg
Solutionoral10 mg/5mL
Tabletoral5 mg/5mg
Tabletoral5 mg/1
Dropsophthalmic; topical0.5 %
Tabletoral5 mg
Suspensionophthalmic10 mg/mL
Liquidoral5 mg
Solutionoral5 mg
Dropsophthalmic1 %
Suspension/ dropsophthalmic10 mg/mL
Suspension/ dropsophthalmic1.2 mg/mL
Dropsophthalmic0.12 %
Ointmentophthalmic
Suspension/ dropsophthalmic
Solutionoral15 mg/5mL
Syruporal15 mg/5mL
Syruporal5 mg/5mL
Suspension/ dropsophthalmic10 mg/1
Solutionoral5 mg/5mL
Solution/ dropsophthalmic10 mg/mL
Tablet, orally disintegratingoral10 mg/1
Tablet, orally disintegratingoral15 mg/1
Tablet, orally disintegratingoral30 mg/1
Solutionoral25 mg/5mL
Drops; liquidophthalmic1 %
Suspensionophthalmic0.12 %
Suspensionophthalmic1 %
Solutionophthalmic
Solution/ dropsophthalmic
Liquidophthalmic
Solutionoral20 mg/5mL
Prices
Unit descriptionCostUnit
Orapred ODT 48 15 mg Dispersible Tablet Box289.42USD box
Pred Forte 1% Suspension 15ml Bottle97.79USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 10ml Bottle72.82USD bottle
Pred Forte 1% Suspension 10ml Bottle68.06USD bottle
Econopred Plus 1% Suspension 10ml Bottle63.44USD bottle
Solu-Medrol Act-O-Vial 1 g/vial61.25USD vial
Solu-Medrol 1 g/vial60.04USD vial
Pediapred 6.7 mg/5ml Solution 120ml Bottle57.77USD bottle
Pred Mild 0.12% Suspension 10ml Bottle44.33USD bottle
Econopred Plus 1% Suspension 5ml Bottle40.99USD bottle
Solu-Medrol Act-O-Vial 500 mg/vial39.96USD vial
Medrol (Pak) 21 4 mg tablet Disp Pack39.3USD disp
Solu-Medrol 500 mg/vial39.17USD vial
Pred Forte 1% Suspension 5ml Bottle37.12USD bottle
Prednisolone sod ph powder36.11USD g
PrednisoLONE Acetate 1% Suspension 15ml Bottle35.46USD bottle
PrednisoLONE Sodium Phosphate 1% Solution 15ml Bottle34.41USD bottle
Pred Mild 0.12% Suspension 5ml Bottle33.98USD bottle
Methylprednisolone Sod Succin. 1 g/vial32.47USD vial
Solu-medrol 1 gm vial24.43USD vial
PrednisoLONE Acetate 1% Suspension 10ml Bottle24.02USD bottle
Solu-medrol (pf) 500 mg vial20.9USD vial
PrednisoLONE Sodium Phosphate 1% Solution 5ml Bottle19.99USD bottle
Methylprednisolone Sod Succin. 500 mg/vial19.48USD vial
PrednisoLONE Acetate 1% Suspension 5ml Bottle15.99USD bottle
Solu-Medrol Act-O-Vial 125 mg/vial15.94USD vial
Solu-medrol 500 mg vial12.9USD vial
Depo-medrol 80 mg/ml vial11.67USD ml
Depo-Medrol 80 mg/ml11.51USD ml
Pred forte 1% eye drops10.32USD ml
Methylprednisolone Acetate 80 mg/ml9.01USD ml
Methylprednisolone Sod Succin. 125 mg/vial8.9USD vial
Depo-Medrol (Preserved) 80 mg/ml8.89USD ml
Orapred odt 30 mg tablet8.34USD tablet
Orapred odt 15 mg tablet7.97USD tablet
Methylprednisolone Acetate (P) 80 mg/ml6.97USD ml
Omnipred 1% eye drops6.78USD ml
Solu-Medrol Act-O-Vial 40 mg/vial6.72USD vial
Depo-medrol 40 mg/ml vial6.41USD ml
Depo-Medrol 40 mg/ml6.01USD ml
Pred Forte 1 % Suspension5.95USD ml
Solu-medrol (pf) 125 mg vial5.83USD vial
Depo-Medrol (Preserved) 40 mg/ml5.75USD ml
Prednisolone ac 1% eye drop5.75USD ml
Prednisol 1% eye drops5.69USD ml
Pred mild 0.12% eye drops5.14USD ml
Medrol 32 mg tablet5.13USD tablet
Methylprednisolone Acetate 40 mg/ml4.71USD ml
Methylprednisolone Acetate (P) 40 mg/ml4.5USD ml
Econopred plus 1% eye drops3.93USD ml
Orapred odt 10 mg tablet3.89USD tablet
Depo-medrol 20 mg/ml vial3.78USD ml
Methylprednisolone Sod Succin. 40 mg/vial3.77USD vial
Prednisolone sod 1% eye drops3.7USD ml
Medrol 16 mg tablet3.5USD tablet
Prednisolone acetate powder3.36USD g
Prednisolone powder3.36USD g
Depo-Medrol 20 mg/ml2.63USD ml
Medrol 8 mg tablet2.3USD tablet
Ratio-Prednisolone 1 % Suspension2.03USD ml
Sandoz Prednisolone Acetate 1 % Suspension2.03USD ml
Pred Mild 0.12 % Suspension2.02USD ml
Medrol 4 mg tablet1.69USD tablet
Medrol 4 mg dosepak1.59USD each
Sandoz Prednisolone Acetate 0.12 % Suspension1.33USD ml
Millipred dp 5 mg dose pack tablet1.18USD tablet
Medrol 2 mg tablet0.84USD tablet
Orapred 15 mg/5 ml solution0.74USD ml
Millipred 5 mg tablet0.59USD tablet
Prelone 15 mg/5 ml syrup0.54USD ml
Prelone 15 mg/5ml Syrup0.47USD ml
PrednisoLONE Sodium Phosphate 15 mg/5ml Solution0.33USD ml
PrednisoLONE Sodium Phosphate 5 mg/5ml Solution0.23USD ml
Prednisolone 5 mg tablet0.14USD tablet
Pediapred 1 mg/ml Liquid0.14USD ml
Pms-Prednisolone 1 mg/ml Liquid0.07USD ml
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Patent NumberPediatric ExtensionApprovedExpires (estimated)
US5178878 No1993-01-122010-01-12Us
US5881926 No1996-03-162016-03-16Us
US6024981 No1998-04-092018-04-09Us
US6071523 No1998-06-032018-06-03Us
US6221392 No1998-04-092018-04-09Us
US6399079 No1998-06-032018-06-03Us
US6656482 No1998-06-032018-06-03Us
US6740341 No1999-11-242019-11-24Us
US7799331 No2008-10-112028-10-11Us
Properties
StateSolid
Experimental Properties
PropertyValueSource
melting point235 °CPhysProp
water solubility223 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP1.62HANSCH,C ET AL. (1995)
logS-3.21ADME Research, USCD
Predicted Properties
PropertyValueSource
Water Solubility0.239 mg/mLALOGPS
logP1.66ALOGPS
logP1.27ChemAxon
logS-3.2ALOGPS
pKa (Strongest Acidic)12.58ChemAxon
pKa (Strongest Basic)-2.9ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count5ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area94.83 Å2ChemAxon
Rotatable Bond Count2ChemAxon
Refractivity98.49 m3·mol-1ChemAxon
Polarizability38.78 Å3ChemAxon
Number of Rings4ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterYesChemAxon
Veber's RuleYesChemAxon
MDDR-like RuleYesChemAxon
Spectra
Mass Spec (NIST)Not Available
Spectra
Spectrum TypeDescriptionSplash Key
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, PositiveNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 10V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 20V, NegativeNot Available
Predicted LC-MS/MSPredicted LC-MS/MS Spectrum - 40V, NegativeNot Available
References
Synthesis Reference

Gunther Bellmann, “Process for producing a sterile prednisolone gel.” U.S. Patent US5811417, issued September 22, 1998.

US5811417
General ReferencesNot Available
External Links
ATC CodesR01AD52D07AA03S02BA03S01CB02D07XA02D07CA03V03AB05S01CA02A07EA01C05AA04S02CA01A01AC54S03BA02S03CA02R01AD02S01BB02S01BA04H02AB06D07BA01
AHFS Codes
  • 52:08.08
  • 68:04.00
PDB EntriesNot Available
FDA labelDownload (101 KB)
MSDSDownload (72.6 KB)
Interactions
Drug Interactions
Drug
1,10-PhenanthrolineThe risk or severity of adverse effects can be increased when Prednisolone is combined with 1,10-Phenanthroline.
AcarboseThe therapeutic efficacy of Acarbose can be decreased when used in combination with Prednisolone.
AcetaminophenThe serum concentration of Prednisolone can be increased when it is combined with Acetaminophen.
AcetohexamideThe therapeutic efficacy of Acetohexamide can be decreased when used in combination with Prednisolone.
AcetyldigitoxinAcetyldigitoxin may decrease the cardiotoxic activities of Prednisolone.
Acetylsalicylic acidThe risk or severity of adverse effects can be increased when Acetylsalicylic acid is combined with Prednisolone.
AfatinibThe serum concentration of Prednisolone can be increased when it is combined with Afatinib.
AicarThe therapeutic efficacy of Aicar can be decreased when used in combination with Prednisolone.
AlbendazoleThe serum concentration of Prednisolone can be increased when it is combined with Albendazole.
AldesleukinPrednisolone may decrease the antineoplastic activities of Aldesleukin.
AldosteroneThe serum concentration of Prednisolone can be decreased when it is combined with Aldosterone.
AlectinibThe serum concentration of Prednisolone can be increased when it is combined with Alectinib.
AlfentanilThe serum concentration of Prednisolone can be increased when it is combined with Alfentanil.
AlogliptinThe therapeutic efficacy of Alogliptin can be decreased when used in combination with Prednisolone.
Aluminum hydroxideThe bioavailability of Prednisolone can be decreased when combined with Aluminum hydroxide.
Aluminum phosphateThe bioavailability of Prednisolone can be decreased when combined with Aluminum phosphate.
AmantadineThe serum concentration of Prednisolone can be increased when it is combined with Amantadine.
AmbenoniumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ambenonium.
Aminohippuric acidThe serum concentration of Prednisolone can be increased when it is combined with Aminohippuric acid.
Aminosalicylic AcidThe risk or severity of adverse effects can be increased when Aminosalicylic Acid is combined with Prednisolone.
AmiodaroneThe serum concentration of Prednisolone can be increased when it is combined with Amiodarone.
AmitriptylineThe serum concentration of Prednisolone can be increased when it is combined with Amitriptyline.
AmlodipineThe serum concentration of Prednisolone can be increased when it is combined with Amlodipine.
Amphotericin BPrednisolone may increase the hypokalemic activities of Amphotericin B.
AmprenavirThe serum concentration of Prednisolone can be decreased when it is combined with Amprenavir.
AmsacrineThe serum concentration of Prednisolone can be increased when it is combined with Amsacrine.
AprepitantThe serum concentration of Prednisolone can be increased when it is combined with Aprepitant.
ArtesunateThe serum concentration of the active metabolites of Artesunate can be reduced when Artesunate is used in combination with Prednisolone resulting in a loss in efficacy.
AstemizoleThe serum concentration of Prednisolone can be increased when it is combined with Astemizole.
AtazanavirThe serum concentration of Prednisolone can be increased when it is combined with Atazanavir.
AtenololThe serum concentration of Prednisolone can be increased when it is combined with Atenolol.
AtomoxetineThe metabolism of Prednisolone can be decreased when combined with Atomoxetine.
AtorvastatinThe serum concentration of Prednisolone can be increased when it is combined with Atorvastatin.
Atracurium besylateAtracurium besylate may increase the adverse neuromuscular activities of Prednisolone.
AzelastineThe serum concentration of Prednisolone can be increased when it is combined with Azelastine.
AzithromycinThe serum concentration of Prednisolone can be increased when it is combined with Azithromycin.
BazedoxifeneThe serum concentration of Prednisolone can be increased when it is combined with Bazedoxifene.
BendroflumethiazidePrednisolone may increase the hypokalemic activities of Bendroflumethiazide.
BenzocaineThe serum concentration of Prednisolone can be increased when it is combined with Benzocaine.
Benzoic AcidThe therapeutic efficacy of Benzoic Acid can be decreased when used in combination with Prednisolone.
BepridilThe serum concentration of Prednisolone can be increased when it is combined with Bepridil.
BevacizumabBevacizumab may increase the cardiotoxic activities of Prednisolone.
BexaroteneThe serum concentration of Prednisolone can be decreased when it is combined with Bexarotene.
BiperidenThe serum concentration of Prednisolone can be increased when it is combined with Biperiden.
Bismuth SubcitrateThe bioavailability of Prednisolone can be decreased when combined with Bismuth Subcitrate.
BoceprevirThe serum concentration of Prednisolone can be increased when it is combined with Boceprevir.
BortezomibThe metabolism of Prednisolone can be decreased when combined with Bortezomib.
BosentanThe serum concentration of Prednisolone can be decreased when it is combined with Bosentan.
BosutinibThe serum concentration of Prednisolone can be increased when it is combined with Bosutinib.
BromocriptineThe serum concentration of Prednisolone can be increased when it is combined with Bromocriptine.
BuforminThe therapeutic efficacy of Buformin can be decreased when used in combination with Prednisolone.
BumetanidePrednisolone may increase the hypokalemic activities of Bumetanide.
BuprenorphineThe serum concentration of Prednisolone can be increased when it is combined with Buprenorphine.
BuspironeThe serum concentration of Prednisolone can be increased when it is combined with Buspirone.
CabazitaxelThe serum concentration of Prednisolone can be increased when it is combined with Cabazitaxel.
CaffeineThe serum concentration of Prednisolone can be increased when it is combined with Caffeine.
CalcitriolThe therapeutic efficacy of Calcitriol can be decreased when used in combination with Prednisolone.
Calcium carbonateThe bioavailability of Prednisolone can be decreased when combined with Calcium carbonate.
CanagliflozinThe therapeutic efficacy of Canagliflozin can be decreased when used in combination with Prednisolone.
CanagliflozinThe serum concentration of Prednisolone can be increased when it is combined with Canagliflozin.
CandesartanThe serum concentration of Prednisolone can be increased when it is combined with Candesartan.
CaptoprilThe serum concentration of Prednisolone can be increased when it is combined with Captopril.
CarbamazepineThe serum concentration of Prednisolone can be decreased when it is combined with Carbamazepine.
CarbimazoleThe serum concentration of Prednisolone can be decreased when it is combined with Carbimazole.
CarvedilolThe serum concentration of Prednisolone can be increased when it is combined with Carvedilol.
CaspofunginThe serum concentration of Prednisolone can be increased when it is combined with Caspofungin.
CastanospermineThe therapeutic efficacy of Castanospermine can be decreased when used in combination with Prednisolone.
CeritinibPrednisolone may increase the hyperglycemic activities of Ceritinib.
CeritinibThe serum concentration of Prednisolone can be increased when it is combined with Ceritinib.
ChloroquineThe serum concentration of Prednisolone can be increased when it is combined with Chloroquine.
ChlorothiazidePrednisolone may increase the hypokalemic activities of Chlorothiazide.
ChlorotrianiseneThe serum concentration of Prednisolone can be increased when it is combined with Chlorotrianisene.
ChlorpromazineThe serum concentration of Prednisolone can be increased when it is combined with Chlorpromazine.
ChlorpropamideThe therapeutic efficacy of Chlorpropamide can be decreased when used in combination with Prednisolone.
ChlorpropamideThe serum concentration of Prednisolone can be increased when it is combined with Chlorpropamide.
ChlorprothixeneThe serum concentration of Prednisolone can be increased when it is combined with Chlorprothixene.
ChlorthalidonePrednisolone may increase the hypokalemic activities of Chlorthalidone.
CholesterolThe serum concentration of Prednisolone can be increased when it is combined with Cholesterol.
CholestyramineCholestyramine can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
Cholic AcidThe serum concentration of Prednisolone can be decreased when it is combined with Cholic Acid.
CiglitazoneThe therapeutic efficacy of Ciglitazone can be decreased when used in combination with Prednisolone.
CilazaprilThe serum concentration of Prednisolone can be increased when it is combined with Cilazapril.
CimetidineThe serum concentration of Prednisolone can be decreased when it is combined with Cimetidine.
CiprofloxacinThe serum concentration of Prednisolone can be increased when it is combined with Ciprofloxacin.
CitalopramThe serum concentration of Prednisolone can be increased when it is combined with Citalopram.
ClarithromycinThe serum concentration of Prednisolone can be increased when it is combined with Clarithromycin.
ClemastineThe metabolism of Prednisolone can be decreased when combined with Clemastine.
ClofazimineThe serum concentration of Prednisolone can be increased when it is combined with Clofazimine.
ClomipramineThe serum concentration of Prednisolone can be increased when it is combined with Clomipramine.
ClotrimazoleThe metabolism of Prednisolone can be decreased when combined with Clotrimazole.
CobicistatThe serum concentration of Prednisolone can be increased when it is combined with Cobicistat.
ColchicineThe serum concentration of Prednisolone can be increased when it is combined with Colchicine.
ColesevelamColesevelam can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColestipolColestipol can cause a decrease in the absorption of Prednisolone resulting in a reduced serum concentration and potentially a decrease in efficacy.
ColforsinThe serum concentration of Prednisolone can be increased when it is combined with Colforsin.
ConivaptanThe serum concentration of Prednisolone can be increased when it is combined with Conivaptan.
Conjugated Equine EstrogensThe serum concentration of Prednisolone can be increased when it is combined with Conjugated Equine Estrogens.
Corticorelin ovine triflutateThe therapeutic efficacy of Corticorelin ovine triflutate can be decreased when used in combination with Prednisolone.
CoumaphosThe risk or severity of adverse effects can be increased when Prednisolone is combined with Coumaphos.
CrizotinibThe metabolism of Prednisolone can be decreased when combined with Crizotinib.
CyclophosphamideCyclophosphamide may increase the cardiotoxic activities of Prednisolone.
CyclosporineThe serum concentration of Cyclosporine can be decreased when it is combined with Prednisolone.
CyclosporineThe metabolism of Prednisolone can be decreased when combined with Cyclosporine.
DabrafenibThe serum concentration of Prednisolone can be decreased when it is combined with Dabrafenib.
DaclatasvirThe serum concentration of Prednisolone can be increased when it is combined with Daclatasvir.
DactinomycinThe serum concentration of Prednisolone can be increased when it is combined with Dactinomycin.
DarunavirThe serum concentration of Prednisolone can be increased when it is combined with Darunavir.
DasatinibThe serum concentration of Prednisolone can be increased when it is combined with Dasatinib.
DaunorubicinThe serum concentration of Prednisolone can be decreased when it is combined with Daunorubicin.
DecamethoniumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Decamethonium.
DeferasiroxThe serum concentration of Prednisolone can be decreased when it is combined with Deferasirox.
DeferasiroxThe risk or severity of adverse effects can be increased when Prednisolone is combined with Deferasirox.
DelavirdineThe metabolism of Prednisolone can be decreased when combined with Delavirdine.
DemecariumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Demecarium.
DenosumabThe risk or severity of adverse effects can be increased when Denosumab is combined with Prednisolone.
DesipramineThe serum concentration of Prednisolone can be increased when it is combined with Desipramine.
DeslanosideDeslanoside may decrease the cardiotoxic activities of Prednisolone.
DesloratadineThe serum concentration of Prednisolone can be increased when it is combined with Desloratadine.
DexamethasoneThe serum concentration of Prednisolone can be decreased when it is combined with Dexamethasone.
DextromethorphanThe serum concentration of Prednisolone can be increased when it is combined with Dextromethorphan.
DichlorvosThe risk or severity of adverse effects can be increased when Prednisolone is combined with Dichlorvos.
DiclofenacThe serum concentration of Prednisolone can be increased when it is combined with Diclofenac.
DienestrolThe serum concentration of Prednisolone can be increased when it is combined with Dienestrol.
DiethylstilbestrolThe serum concentration of Prednisolone can be increased when it is combined with Diethylstilbestrol.
DiflunisalThe risk or severity of adverse effects can be increased when Diflunisal is combined with Prednisolone.
DigitoxinDigitoxin may decrease the cardiotoxic activities of Prednisolone.
DigoxinDigoxin may decrease the cardiotoxic activities of Prednisolone.
DihydroergotamineThe metabolism of Prednisolone can be decreased when combined with Dihydroergotamine.
DihydrotestosteronePrednisolone may increase the fluid retaining activities of Dihydrotestosterone.
DiltiazemThe metabolism of Prednisolone can be decreased when combined with Diltiazem.
DipyridamoleThe serum concentration of Prednisolone can be increased when it is combined with Dipyridamole.
DocetaxelThe risk or severity of adverse effects can be increased when Docetaxel is combined with Prednisolone.
DonepezilThe risk or severity of adverse effects can be increased when Prednisolone is combined with Donepezil.
DoxazosinThe serum concentration of Prednisolone can be increased when it is combined with Doxazosin.
DoxepinThe serum concentration of Prednisolone can be increased when it is combined with Doxepin.
DoxorubicinThe serum concentration of Prednisolone can be decreased when it is combined with Doxorubicin.
DoxycyclineThe metabolism of Prednisolone can be decreased when combined with Doxycycline.
DronabinolThe serum concentration of Prednisolone can be increased when it is combined with Dronabinol.
DronedaroneThe metabolism of Prednisolone can be decreased when combined with Dronedarone.
DulaglutideThe therapeutic efficacy of Dulaglutide can be decreased when used in combination with Prednisolone.
EchothiophateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Echothiophate.
EdrophoniumThe risk or severity of adverse effects can be increased when Prednisolone is combined with Edrophonium.
EfavirenzThe serum concentration of Prednisolone can be decreased when it is combined with Efavirenz.
ElbasvirThe serum concentration of Prednisolone can be increased when it is combined with Elbasvir.
EmpagliflozinThe therapeutic efficacy of Empagliflozin can be decreased when used in combination with Prednisolone.
EnalaprilThe serum concentration of Prednisolone can be increased when it is combined with Enalapril.
EnzalutamideThe serum concentration of Prednisolone can be decreased when it is combined with Enzalutamide.
ErgonovineThe serum concentration of Prednisolone can be increased when it is combined with Ergonovine.
ErgotamineThe serum concentration of Prednisolone can be increased when it is combined with Ergotamine.
ErythromycinThe metabolism of Prednisolone can be decreased when combined with Erythromycin.
Eslicarbazepine acetateThe serum concentration of Prednisolone can be decreased when it is combined with Eslicarbazepine acetate.
EstradiolThe serum concentration of Prednisolone can be increased when it is combined with Estradiol.
EstramustineThe serum concentration of Prednisolone can be increased when it is combined with Estramustine.
EstriolThe serum concentration of Prednisolone can be increased when it is combined with Estriol.
EstroneThe serum concentration of Prednisolone can be increased when it is combined with Estrone.
Etacrynic acidPrednisolone may increase the hypokalemic activities of Etacrynic acid.
Ethinyl EstradiolThe serum concentration of Prednisolone can be increased when it is combined with Ethinyl Estradiol.
EtoposideThe serum concentration of Prednisolone can be increased when it is combined with Etoposide.
EtravirineThe serum concentration of Prednisolone can be decreased when it is combined with Etravirine.
ExenatideThe therapeutic efficacy of Exenatide can be decreased when used in combination with Prednisolone.
FelodipineThe serum concentration of Prednisolone can be increased when it is combined with Felodipine.
FentanylThe serum concentration of Prednisolone can be increased when it is combined with Fentanyl.
FenthionThe risk or severity of adverse effects can be increased when Prednisolone is combined with Fenthion.
FexofenadineThe serum concentration of Prednisolone can be increased when it is combined with Fexofenadine.
FidaxomicinThe serum concentration of Prednisolone can be increased when it is combined with Fidaxomicin.
FingolimodPrednisolone may increase the immunosuppressive activities of Fingolimod.
FluconazoleThe metabolism of Prednisolone can be decreased when combined with Fluconazole.
FluoxetineThe serum concentration of Prednisolone can be increased when it is combined with Fluoxetine.
FluoxymesteronePrednisolone may increase the fluid retaining activities of Fluoxymesterone.
FlupentixolThe serum concentration of Prednisolone can be increased when it is combined with Flupentixol.
FluphenazineThe serum concentration of Prednisolone can be increased when it is combined with Fluphenazine.
FlurazepamThe serum concentration of Prednisolone can be increased when it is combined with Flurazepam.
FluvoxamineThe metabolism of Prednisolone can be decreased when combined with Fluvoxamine.
FosamprenavirThe metabolism of Prednisolone can be decreased when combined with Fosamprenavir.
FosaprepitantThe serum concentration of Prednisolone can be increased when it is combined with Fosaprepitant.
FosphenytoinThe serum concentration of Prednisolone can be decreased when it is combined with Fosphenytoin.
FurosemidePrednisolone may increase the hypokalemic activities of Furosemide.
Fusidic AcidThe serum concentration of Prednisolone can be increased when it is combined with Fusidic Acid.
GalantamineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Galantamine.
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Gallamine Triethiodide.
GefitinibThe serum concentration of Prednisolone can be increased when it is combined with Gefitinib.
GenisteinThe serum concentration of Prednisolone can be increased when it is combined with Genistein.
Ginkgo bilobaThe risk or severity of adverse effects can be increased when Prednisolone is combined with Ginkgo biloba.
GlibornurideThe therapeutic efficacy of Glibornuride can be decreased when used in combination with Prednisolone.
GliclazideThe therapeutic efficacy of Gliclazide can be decreased when used in combination with Prednisolone.
GlimepirideThe therapeutic efficacy of Glimepiride can be decreased when used in combination with Prednisolone.
GlipizideThe therapeutic efficacy of Glipizide can be decreased when used in combination with Prednisolone.
GliquidoneThe therapeutic efficacy of Gliquidone can be decreased when used in combination with Prednisolone.
GlyburideThe therapeutic efficacy of Glyburide can be decreased when used in combination with Prednisolone.
GlyburideThe serum concentration of Prednisolone can be increased when it is combined with Glyburide.
GlycerolThe serum concentration of Prednisolone can be increased when it is combined with Glycerol.
Glycerol PhenylbutyrateThe therapeutic efficacy of Glycerol Phenylbutyrate can be decreased when used in combination with Prednisolone.
Gramicidin DThe serum concentration of Prednisolone can be increased when it is combined with Gramicidin D.
GrepafloxacinThe serum concentration of Prednisolone can be increased when it is combined with Grepafloxacin.
HaloperidolThe serum concentration of Prednisolone can be increased when it is combined with Haloperidol.
HexestrolThe serum concentration of Prednisolone can be increased when it is combined with Hexestrol.
Huperzine AThe risk or severity of adverse effects can be increased when Prednisolone is combined with Huperzine A.
HyaluronidaseThe therapeutic efficacy of Hyaluronidase can be decreased when used in combination with Prednisolone.
HydrochlorothiazidePrednisolone may increase the hypokalemic activities of Hydrochlorothiazide.
HydrocortisoneThe serum concentration of Prednisolone can be increased when it is combined with Hydrocortisone.
HydroflumethiazidePrednisolone may increase the hypokalemic activities of Hydroflumethiazide.
IdelalisibThe serum concentration of Prednisolone can be increased when it is combined with Idelalisib.
ImatinibThe metabolism of Prednisolone can be decreased when combined with Imatinib.
ImipramineThe serum concentration of Prednisolone can be increased when it is combined with Imipramine.
IndacaterolIndacaterol may increase the hypokalemic activities of Prednisolone.
IndapamidePrednisolone may increase the hypokalemic activities of Indapamide.
IndinavirThe serum concentration of Prednisolone can be increased when it is combined with Indinavir.
IndomethacinThe serum concentration of Prednisolone can be increased when it is combined with Indomethacin.
Insulin AspartThe therapeutic efficacy of Insulin Aspart can be decreased when used in combination with Prednisolone.
Insulin DetemirThe therapeutic efficacy of Insulin Detemir can be decreased when used in combination with Prednisolone.
Insulin GlargineThe therapeutic efficacy of Insulin Glargine can be decreased when used in combination with Prednisolone.
Insulin GlulisineThe therapeutic efficacy of Insulin Glulisine can be decreased when used in combination with Prednisolone.
Insulin LisproThe therapeutic efficacy of Insulin Lispro can be decreased when used in combination with Prednisolone.
Insulin PorkThe therapeutic efficacy of Insulin Pork can be decreased when used in combination with Prednisolone.
IsavuconazoniumThe metabolism of Prednisolone can be decreased when combined with Isavuconazonium.
IsoflurophateThe risk or severity of adverse effects can be increased when Prednisolone is combined with Isoflurophate.
IsoniazidThe serum concentration of Isoniazid can be decreased when it is combined with Prednisolone.
IsradipineThe metabolism of Prednisolone can be decreased when combined with Isradipine.
ItraconazoleThe serum concentration of Prednisolone can be increased when it is combined with Itraconazole.
IvacaftorThe serum concentration of Prednisolone can be increased when it is combined with Ivacaftor.
IvermectinThe serum concentration of Prednisolone can be increased when it is combined with Ivermectin.
KetamineThe serum concentration of Prednisolone can be increased when it is combined with Ketamine.
KetoconazoleThe serum concentration of Prednisolone can be increased when it is combined with Ketoconazole.
LansoprazoleThe serum concentration of Prednisolone can be increased when it is combined with Lansoprazole.
LapatinibThe serum concentration of Prednisolone can be increased when it is combined with Lapatinib.
LeflunomideThe risk or severity of adverse effects can be increased when Prednisolone is combined with Leflunomide.
LevofloxacinThe serum concentration of Prednisolone can be increased when it is combined with Levofloxacin.
LevothyroxineThe serum concentration of Prednisolone can be decreased when it is combined with Levothyroxine.
LidocaineThe serum concentration of Prednisolone can be increased when it is combined with Lidocaine.
LinagliptinThe therapeutic efficacy of Linagliptin can be decreased when used in combination with Prednisolone.
LiothyronineThe serum concentration of Prednisolone can be decreased when it is combined with Liothyronine.
LiotrixThe serum concentration of Prednisolone can be decreased when it is combined with Liotrix.
LiraglutideThe therapeutic efficacy of Liraglutide can be decreased when used in combination with Prednisolone.
LisinoprilThe serum concentration of Prednisolone can be increased when it is combined with Lisinopril.
LomitapideThe serum concentration of Prednisolone can be increased when it is combined with Lomitapide.
LoperamideThe serum concentration of Prednisolone can be increased when it is combined with Loperamide.
LopinavirThe serum concentration of Prednisolone can be increased when it is combined with Lopinavir.
LoratadineThe serum concentration of Prednisolone can be increased when it is combined with Loratadine.
LosartanThe serum concentration of Prednisolone can be increased when it is combined with Losartan.
LovastatinThe metabolism of Prednisolone can be decreased when combined with Lovastatin.
LuliconazoleThe serum concentration of Prednisolone can be increased when it is combined with Luliconazole.
LumacaftorThe serum concentration of Prednisolone can be decreased when it is combined with Lumacaftor.
MagaldrateThe bioavailability of Prednisolone can be decreased when combined with Magaldrate.
Magnesium carbonateThe bioavailability of Prednisolone can be decreased when combined with Magnesium carbonate.
Magnesium hydroxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium hydroxide.
Magnesium oxideThe bioavailability of Prednisolone can be decreased when combined with Magnesium oxide.
Magnesium TrisilicateThe bioavailability of Prednisolone can be decreased when combined with Magnesium Trisilicate.
MalathionThe risk or severity of adverse effects can be increased when Prednisolone is combined with Malathion.
MaprotilineThe serum concentration of Prednisolone can be increased when it is combined with Maprotiline.
MebendazoleThe serum concentration of Prednisolone can be increased when it is combined with Mebendazole.
MefloquineThe serum concentration of Prednisolone can be increased when it is combined with Mefloquine.
MefloquineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Mefloquine.
Megestrol acetateThe serum concentration of Prednisolone can be increased when it is combined with Megestrol acetate.
MemantineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Memantine.
MeprobamateThe serum concentration of Prednisolone can be increased when it is combined with Meprobamate.
MesalazineThe risk or severity of adverse effects can be increased when Mesalazine is combined with Prednisolone.
MestranolThe serum concentration of Prednisolone can be increased when it is combined with Mestranol.
MetforminThe therapeutic efficacy of Metformin can be decreased when used in combination with Prednisolone.
MethadoneThe serum concentration of Prednisolone can be increased when it is combined with Methadone.
MethimazoleThe serum concentration of Prednisolone can be decreased when it is combined with Methimazole.
MethyclothiazidePrednisolone may increase the hypokalemic activities of Methyclothiazide.
MethyltestosteronePrednisolone may increase the fluid retaining activities of Methyltestosterone.
MetolazonePrednisolone may increase the hypokalemic activities of Metolazone.
MetoprololThe serum concentration of Prednisolone can be increased when it is combined with Metoprolol.
MibefradilThe serum concentration of Prednisolone can be increased when it is combined with Mibefradil.
MiconazoleThe serum concentration of Prednisolone can be increased when it is combined with Miconazole.
MidazolamThe serum concentration of Prednisolone can be decreased when it is combined with Midazolam.
MifepristoneThe therapeutic efficacy of Prednisolone can be decreased when used in combination with Mifepristone.
MiglitolThe therapeutic efficacy of Miglitol can be decreased when used in combination with Prednisolone.
MiglustatThe therapeutic efficacy of Miglustat can be decreased when used in combination with Prednisolone.
MinaprineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Minaprine.
MitiglinideThe therapeutic efficacy of Mitiglinide can be decreased when used in combination with Prednisolone.
MitomycinThe serum concentration of Prednisolone can be increased when it is combined with Mitomycin.
MitotaneThe serum concentration of Prednisolone can be decreased when it is combined with Mitotane.
MitoxantroneThe serum concentration of Prednisolone can be decreased when it is combined with Mitoxantrone.
MivacuriumMivacurium may increase the adverse neuromuscular activities of Prednisolone.
ModafinilThe serum concentration of Prednisolone can be decreased when it is combined with Modafinil.
MorphineThe serum concentration of Prednisolone can be increased when it is combined with Morphine.
NafcillinThe serum concentration of Prednisolone can be decreased when it is combined with Nafcillin.
NaltrexoneThe serum concentration of Prednisolone can be increased when it is combined with Naltrexone.
NaringeninThe serum concentration of Prednisolone can be increased when it is combined with Naringenin.
NatalizumabThe risk or severity of adverse effects can be increased when Prednisolone is combined with Natalizumab.
NateglinideThe therapeutic efficacy of Nateglinide can be decreased when used in combination with Prednisolone.
NefazodoneThe serum concentration of Prednisolone can be increased when it is combined with Nefazodone.
NelfinavirThe serum concentration of Prednisolone can be increased when it is combined with Nelfinavir.
NeostigmineThe serum concentration of Prednisolone can be increased when it is combined with Neostigmine.
NeostigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Neostigmine.
NetupitantThe serum concentration of Prednisolone can be increased when it is combined with Netupitant.
NevirapineThe serum concentration of Prednisolone can be decreased when it is combined with Nevirapine.
NicardipineThe serum concentration of Prednisolone can be increased when it is combined with Nicardipine.
NicorandilThe risk or severity of adverse effects can be increased when Prednisolone is combined with Nicorandil.
NifedipineThe serum concentration of Prednisolone can be decreased when it is combined with Nifedipine.
NilotinibThe metabolism of Prednisolone can be decreased when combined with Nilotinib.
NintedanibThe serum concentration of Nintedanib can be increased when it is combined with Prednisolone.
NisoldipineThe serum concentration of Prednisolone can be increased when it is combined with Nisoldipine.
NitrazepamThe serum concentration of Prednisolone can be increased when it is combined with Nitrazepam.
NitrendipineThe serum concentration of Prednisolone can be increased when it is combined with Nitrendipine.
NorethisteroneThe serum concentration of Prednisolone can be decreased when it is combined with Norethisterone.
OlaparibThe metabolism of Prednisolone can be decreased when combined with Olaparib.
OmeprazoleThe serum concentration of Prednisolone can be increased when it is combined with Omeprazole.
OsimertinibThe serum concentration of Prednisolone can be increased when it is combined with Osimertinib.
OuabainOuabain may decrease the cardiotoxic activities of Prednisolone.
OxandrolonePrednisolone may increase the fluid retaining activities of Oxandrolone.
OxymetholonePrednisolone may increase the fluid retaining activities of Oxymetholone.
P-NitrophenolThe serum concentration of Prednisolone can be increased when it is combined with P-Nitrophenol.
PaclitaxelThe serum concentration of Prednisolone can be increased when it is combined with Paclitaxel.
PalbociclibThe serum concentration of Prednisolone can be increased when it is combined with Palbociclib.
Palmitic AcidThe serum concentration of Prednisolone can be increased when it is combined with Palmitic Acid.
PantoprazoleThe serum concentration of Prednisolone can be increased when it is combined with Pantoprazole.
ParoxetineThe serum concentration of Prednisolone can be increased when it is combined with Paroxetine.
PentobarbitalThe serum concentration of Prednisolone can be decreased when it is combined with Pentobarbital.
PerindoprilThe serum concentration of Prednisolone can be increased when it is combined with Perindopril.
PhenforminThe therapeutic efficacy of Phenformin can be decreased when used in combination with Prednisolone.
PhenobarbitalThe serum concentration of Prednisolone can be decreased when it is combined with Phenobarbital.
Phenylacetic acidThe therapeutic efficacy of Phenylacetic acid can be decreased when used in combination with Prednisolone.
PhenytoinThe serum concentration of Prednisolone can be decreased when it is combined with Phenytoin.
PhysostigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Physostigmine.
PimecrolimusThe risk or severity of adverse effects can be increased when Pimecrolimus is combined with Prednisolone.
PimozideThe serum concentration of Prednisolone can be increased when it is combined with Pimozide.
PioglitazoneThe therapeutic efficacy of Pioglitazone can be decreased when used in combination with Prednisolone.
PiretanidePrednisolone may increase the hypokalemic activities of Piretanide.
Platelet Activating FactorThe serum concentration of Prednisolone can be decreased when it is combined with Platelet Activating Factor.
Polyestradiol phosphateThe serum concentration of Prednisolone can be increased when it is combined with Polyestradiol phosphate.
PolythiazidePrednisolone may increase the hypokalemic activities of Polythiazide.
PonatinibThe serum concentration of Prednisolone can be increased when it is combined with Ponatinib.
PosaconazoleThe serum concentration of Prednisolone can be increased when it is combined with Posaconazole.
PramlintideThe therapeutic efficacy of Pramlintide can be decreased when used in combination with Prednisolone.
PravastatinThe serum concentration of Prednisolone can be increased when it is combined with Pravastatin.
PrazosinThe serum concentration of Prednisolone can be increased when it is combined with Prazosin.
PrednisoneThe serum concentration of Prednisolone can be increased when it is combined with Prednisone.
PrimidoneThe serum concentration of Prednisolone can be decreased when it is combined with Primidone.
ProbenecidThe serum concentration of Prednisolone can be increased when it is combined with Probenecid.
ProgesteroneThe serum concentration of Prednisolone can be decreased when it is combined with Progesterone.
PromethazineThe serum concentration of Prednisolone can be increased when it is combined with Promethazine.
PropafenoneThe serum concentration of Prednisolone can be increased when it is combined with Propafenone.
PropranololThe serum concentration of Prednisolone can be increased when it is combined with Propranolol.
ProtriptylineThe serum concentration of Prednisolone can be increased when it is combined with Protriptyline.
PyridostigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Pyridostigmine.
QuercetinThe serum concentration of Prednisolone can be increased when it is combined with Quercetin.
QuinacrineThe serum concentration of Prednisolone can be increased when it is combined with Quinacrine.
QuinestrolThe serum concentration of Prednisolone can be increased when it is combined with Quinestrol.
QuinethazonePrednisolone may increase the hypokalemic activities of Quinethazone.
QuinidineThe serum concentration of Prednisolone can be increased when it is combined with Quinidine.
QuinineThe serum concentration of Prednisolone can be increased when it is combined with Quinine.
Rabies vaccineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rabies vaccine.
RanitidineThe serum concentration of Prednisolone can be increased when it is combined with Ranitidine.
RanolazineThe serum concentration of Prednisolone can be increased when it is combined with Ranolazine.
RapacuroniumRapacuronium may increase the adverse neuromuscular activities of Prednisolone.
ReboxetineThe serum concentration of Prednisolone can be increased when it is combined with Reboxetine.
RegorafenibThe serum concentration of Prednisolone can be increased when it is combined with Regorafenib.
RepaglinideThe therapeutic efficacy of Repaglinide can be decreased when used in combination with Prednisolone.
ReserpineThe serum concentration of Prednisolone can be decreased when it is combined with Reserpine.
RifabutinThe serum concentration of Prednisolone can be decreased when it is combined with Rifabutin.
RifampicinThe serum concentration of Prednisolone can be decreased when it is combined with Rifampicin.
RifapentineThe serum concentration of Prednisolone can be decreased when it is combined with Rifapentine.
RilpivirineThe serum concentration of Prednisolone can be increased when it is combined with Rilpivirine.
RitonavirThe serum concentration of Prednisolone can be increased when it is combined with Ritonavir.
RivastigmineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Rivastigmine.
RoflumilastRoflumilast may increase the immunosuppressive activities of Prednisolone.
RolapitantThe serum concentration of Prednisolone can be increased when it is combined with Rolapitant.
RosiglitazoneThe therapeutic efficacy of Rosiglitazone can be decreased when used in combination with Prednisolone.
Salicylic acidThe risk or severity of adverse effects can be increased when Salicylic acid is combined with Prednisolone.
SaquinavirThe serum concentration of Prednisolone can be increased when it is combined with Saquinavir.
SaxagliptinThe therapeutic efficacy of Saxagliptin can be decreased when used in combination with Prednisolone.
ScopolamineThe serum concentration of Prednisolone can be increased when it is combined with Scopolamine.
SelegilineThe serum concentration of Prednisolone can be increased when it is combined with Selegiline.
SertralineThe serum concentration of Prednisolone can be increased when it is combined with Sertraline.
SildenafilThe metabolism of Prednisolone can be decreased when combined with Sildenafil.
SiltuximabThe serum concentration of Prednisolone can be decreased when it is combined with Siltuximab.
SimeprevirThe serum concentration of Prednisolone can be increased when it is combined with Simeprevir.
SimvastatinThe serum concentration of Prednisolone can be increased when it is combined with Simvastatin.
Sipuleucel-TThe therapeutic efficacy of Sipuleucel-T can be decreased when used in combination with Prednisolone.
SirolimusThe serum concentration of Prednisolone can be decreased when it is combined with Sirolimus.
SitagliptinThe therapeutic efficacy of Sitagliptin can be decreased when used in combination with Prednisolone.
Sodium phenylbutyrateThe therapeutic efficacy of Sodium phenylbutyrate can be decreased when used in combination with Prednisolone.
SorafenibThe serum concentration of Prednisolone can be increased when it is combined with Sorafenib.
SpironolactoneThe serum concentration of Prednisolone can be increased when it is combined with Spironolactone.
St. John's WortThe serum concentration of Prednisolone can be decreased when it is combined with St. John's Wort.
StanozololPrednisolone may increase the fluid retaining activities of Stanozolol.
StaurosporineThe serum concentration of Prednisolone can be increased when it is combined with Staurosporine.
StiripentolThe serum concentration of Prednisolone can be increased when it is combined with Stiripentol.
StreptozocinThe serum concentration of Prednisolone can be decreased when it is combined with Streptozocin.
SulfinpyrazoneThe serum concentration of Prednisolone can be increased when it is combined with Sulfinpyrazone.
SulfisoxazoleThe metabolism of Prednisolone can be decreased when combined with Sulfisoxazole.
SulodexideThe therapeutic efficacy of Sulodexide can be decreased when used in combination with Prednisolone.
SumatriptanThe serum concentration of Prednisolone can be increased when it is combined with Sumatriptan.
SunitinibThe serum concentration of Prednisolone can be increased when it is combined with Sunitinib.
Synthetic Conjugated Estrogens, AThe serum concentration of Prednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, A.
Synthetic Conjugated Estrogens, BThe serum concentration of Prednisolone can be increased when it is combined with Synthetic Conjugated Estrogens, B.
TacrineThe serum concentration of Prednisolone can be increased when it is combined with Tacrine.
TacrineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tacrine.
TacrolimusThe risk or severity of adverse effects can be increased when Tacrolimus is combined with Prednisolone.
TamoxifenThe serum concentration of Prednisolone can be decreased when it is combined with Tamoxifen.
Taurocholic AcidThe serum concentration of Prednisolone can be increased when it is combined with Taurocholic Acid.
TelaprevirThe serum concentration of Telaprevir can be decreased when it is combined with Prednisolone.
TelaprevirThe serum concentration of Prednisolone can be increased when it is combined with Telaprevir.
TelithromycinThe serum concentration of Prednisolone can be increased when it is combined with Telithromycin.
TelmisartanThe serum concentration of Prednisolone can be increased when it is combined with Telmisartan.
TemsirolimusThe serum concentration of Prednisolone can be increased when it is combined with Temsirolimus.
TerazosinThe serum concentration of Prednisolone can be increased when it is combined with Terazosin.
TerfenadineThe serum concentration of Prednisolone can be increased when it is combined with Terfenadine.
TesmilifeneThe serum concentration of Prednisolone can be decreased when it is combined with Tesmilifene.
TestosteronePrednisolone may increase the fluid retaining activities of Testosterone.
TestosteroneThe serum concentration of Prednisolone can be increased when it is combined with Testosterone.
TiboloneThe serum concentration of Prednisolone can be increased when it is combined with Tibolone.
TicagrelorThe serum concentration of Prednisolone can be increased when it is combined with Ticagrelor.
TiclopidineThe metabolism of Prednisolone can be decreased when combined with Ticlopidine.
TocilizumabThe serum concentration of Prednisolone can be decreased when it is combined with Tocilizumab.
TofacitinibPrednisolone may increase the immunosuppressive activities of Tofacitinib.
TolazamideThe therapeutic efficacy of Tolazamide can be decreased when used in combination with Prednisolone.
TolbutamideThe therapeutic efficacy of Tolbutamide can be decreased when used in combination with Prednisolone.
TolvaptanThe serum concentration of Prednisolone can be increased when it is combined with Tolvaptan.
TorasemidePrednisolone may increase the hypokalemic activities of Torasemide.
TrastuzumabTrastuzumab may increase the neutropenic activities of Prednisolone.
TrazodoneThe serum concentration of Prednisolone can be decreased when it is combined with Trazodone.
TrichlorfonThe risk or severity of adverse effects can be increased when Prednisolone is combined with Trichlorfon.
TrichlormethiazidePrednisolone may increase the hypokalemic activities of Trichlormethiazide.
TrifluoperazineThe serum concentration of Prednisolone can be increased when it is combined with Trifluoperazine.
TriflupromazineThe serum concentration of Prednisolone can be increased when it is combined with Triflupromazine.
TrimethoprimThe serum concentration of Prednisolone can be decreased when it is combined with Trimethoprim.
TrimipramineThe serum concentration of Prednisolone can be increased when it is combined with Trimipramine.
TroglitazoneThe therapeutic efficacy of Troglitazone can be decreased when used in combination with Prednisolone.
TroleandomycinThe serum concentration of Prednisolone can be increased when it is combined with Troleandomycin.
TubocurarineThe risk or severity of adverse effects can be increased when Prednisolone is combined with Tubocurarine.
VenlafaxineThe metabolism of Prednisolone can be decreased when combined with Venlafaxine.
VerapamilThe metabolism of Prednisolone can be decreased when combined with Verapamil.
VildagliptinThe therapeutic efficacy of Vildagliptin can be decreased when used in combination with Prednisolone.
VinblastineThe serum concentration of Prednisolone can be decreased when it is combined with Vinblastine.
VincristineThe serum concentration of Prednisolone can be decreased when it is combined with Vincristine.
VinorelbineThe serum concentration of Prednisolone can be increased when it is combined with Vinorelbine.
VogliboseThe therapeutic efficacy of Voglibose can be decreased when used in combination with Prednisolone.
VoriconazoleThe serum concentration of Prednisolone can be increased when it is combined with Voriconazole.
WarfarinPrednisolone may increase the anticoagulant activities of Warfarin.
ZeranolThe serum concentration of Prednisolone can be increased when it is combined with Zeranol.
ZimelidineThe serum concentration of Prednisolone can be increased when it is combined with Zimelidine.
ZiprasidoneThe metabolism of Prednisolone can be decreased when combined with Ziprasidone.
Food Interactions
  • Avoid alcohol. Avoid caffeine.
  • Take with food to reduce gastric irritation.

Targets

Kind
Protein
Organism
Human
Pharmacological action
yes
Actions
agonist
General Function:
Zinc ion binding
Specific Function:
Receptor for glucocorticoids (GC). Has a dual mode of action: as a transcription factor that binds to glucocorticoid response elements (GRE), both for nuclear and mitochondrial DNA, and as a modulator of other transcription factors. Affects inflammatory responses, cellular proliferation and differentiation in target tissues. Could act as a coactivator for STAT5-dependent transcription upon grow...
Gene Name:
NR3C1
Uniprot ID:
P04150
Molecular Weight:
85658.57 Da
References
  1. Ikonomidis I, Tzortzis S, Lekakis J, Paraskevaidis I, Andreadou I, Nikolaou M, Kaplanoglou T, Katsimbri P, Skarantavos G, Soucacos P, Kremastinos DT: Lowering interleukin-1 activity with anakinra improves myocardial deformation in rheumatoid arthritis. Heart. 2009 Sep;95(18):1502-7. doi: 10.1136/hrt.2009.168971. Epub 2009 May 28. [PubMed:19482847 ]
  2. Boudinot FD, D'Ambrosio R, Jusko WJ: Receptor-mediated pharmacodynamics of prednisolone in the rat. J Pharmacokinet Biopharm. 1986 Oct;14(5):469-93. [PubMed:2879901 ]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrateinhibitor
General Function:
Vitamin d3 25-hydroxylase activity
Specific Function:
Cytochromes P450 are a group of heme-thiolate monooxygenases. In liver microsomes, this enzyme is involved in an NADPH-dependent electron transport pathway. It performs a variety of oxidation reactions (e.g. caffeine 8-oxidation, omeprazole sulphoxidation, midazolam 1'-hydroxylation and midazolam 4-hydroxylation) of structurally unrelated compounds, including steroids, fatty acids, and xenobiot...
Gene Name:
CYP3A4
Uniprot ID:
P08684
Molecular Weight:
57342.67 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Steroid hydroxylase activity
Specific Function:
Exhibits a high coumarin 7-hydroxylase activity. Can act in the hydroxylation of the anti-cancer drugs cyclophosphamide and ifosphamide. Competent in the metabolic activation of aflatoxin B1. Constitutes the major nicotine C-oxidase. Acts as a 1,4-cineole 2-exo-monooxygenase. Possesses low phenacetin O-deethylation activity.
Gene Name:
CYP2A6
Uniprot ID:
P11509
Molecular Weight:
56501.005 Da
References
  1. Preissner S, Kroll K, Dunkel M, Senger C, Goldsobel G, Kuzman D, Guenther S, Winnenburg R, Schroeder M, Preissner R: SuperCYP: a comprehensive database on Cytochrome P450 enzymes including a tool for analysis of CYP-drug interactions. Nucleic Acids Res. 2010 Jan;38(Database issue):D237-43. doi: 10.1093/nar/gkp970. Epub 2009 Nov 24. [PubMed:19934256 ]

Carriers

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
binder
General Function:
Steroid binding
Specific Function:
Major transport protein for glucocorticoids and progestins in the blood of almost all vertebrate species.
Gene Name:
SERPINA6
Uniprot ID:
P08185
Molecular Weight:
45140.49 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284 ]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423 ]
  3. Frey BM, Frey FJ: Estimation of transcortin concentration by measurements of plasma protein-binding of prednisolone and by electroimmunodiffusion. Br J Clin Pharmacol. 1982 Feb;13(2):245-9. [PubMed:6800390 ]
  4. Ko HC, Almon RR, Jusko WJ: Effect of corticosteroid binding globulin on the pharmacokinetics of prednisolone in rats. Pharm Res. 1995 Jun;12(6):902-4. [PubMed:7667198 ]
  5. Angeli A, Frajria R, De Paoli R, Fonzo D, Ceresa F: Diurnal variation of prednisolone binding to serum corticosteroid-binding globulin in man. Clin Pharmacol Ther. 1978 Jan;23(1):47-53. [PubMed:563315 ]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352 ]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
inhibitor
General Function:
Sodium-independent organic anion transmembrane transporter activity
Specific Function:
Mediates the Na(+)-independent transport of organic anions such as sulfobromophthalein (BSP) and conjugated (taurocholate) and unconjugated (cholate) bile acids (By similarity). Selectively inhibited by the grapefruit juice component naringin.
Gene Name:
SLCO1A2
Uniprot ID:
P46721
Molecular Weight:
74144.105 Da
References
  1. Bossuyt X, Muller M, Hagenbuch B, Meier PJ: Polyspecific drug and steroid clearance by an organic anion transporter of mammalian liver. J Pharmacol Exp Ther. 1996 Mar;276(3):891-6. [PubMed:8786566 ]
Kind
Protein
Organism
Human
Pharmacological action
unknown
Actions
substrate
General Function:
Xenobiotic-transporting atpase activity
Specific Function:
Energy-dependent efflux pump responsible for decreased drug accumulation in multidrug-resistant cells.
Gene Name:
ABCB1
Uniprot ID:
P08183
Molecular Weight:
141477.255 Da
References
  1. Troutman MD, Thakker DR: Novel experimental parameters to quantify the modulation of absorptive and secretory transport of compounds by P-glycoprotein in cell culture models of intestinal epithelium. Pharm Res. 2003 Aug;20(8):1210-24. [PubMed:12948019 ]
  2. Yates CR, Chang C, Kearbey JD, Yasuda K, Schuetz EG, Miller DD, Dalton JT, Swaan PW: Structural determinants of P-glycoprotein-mediated transport of glucocorticoids. Pharm Res. 2003 Nov;20(11):1794-803. [PubMed:14661924 ]
Comments
comments powered by Disqus
Drug created on June 13, 2005 07:24 / Updated on September 28, 2016 02:26